Table 1.
Clinical and pathologic characteristics of the patient cohort (N=222)
| Variable | All (N=222) | GRCC (N=111) | DEN (N=77) | MSK (N=34) | p* |
|---|---|---|---|---|---|
|
| |||||
| N (%) | N (%) | N (%) | N (%) | ||
| Age at Diagnosis | |||||
| Median | 49 | 39 | 60 | 54 | <0.001 |
| Range | 15–89 | 15–83 | 21–89 | 20–86 | |
|
| |||||
| Smoker (9 missing) | |||||
| Yes | 78 (37%) | 20 (19%) | 44 (59%) | 14 (42%) | <0.001 |
|
| |||||
| Stage (1 missing) | |||||
| I | 163 (74%) | 85 (77%) | 52 (68%) | 26 (76%) | 0.454 |
|
| |||||
| IA | 100 (45%) | 45 (41%) | 38 (50%) | 17 (50%) | |
| IB | 1 (0.5%) | 0 (0%) | 1 (1%) | 0 (0%) | |
| IC | 22 (10%) | 0 (0%) | 13 (17%) | 9 (26%) | |
| ICI | 15 (7%) | 15 (14%) | 0 (0%) | 0 (0%) | |
| IC2 | 20 (9%) | 20 (18%) | 0 (0%) | 0 (0%) | |
| IC3 | 5 (2%) | 5 (5%) | 0 (0%) | 0 (0%) | |
| II/III/IV | 58 (26%) | 26 (23%) | 24 (32%) | 8 (24%) | |
|
| |||||
| IIA | 1 (0.5%) | 0 (0%) | 1 (1%) | 0 (0%) | |
| IIB | 4 (2%) | 1 (1%) | 3 (4%) | 0 (0%) | |
| IIC | 3 (1%) | 0 (0%) | 0 (0%) | 3 (9%) | |
| IIIA | 1 (0.5%) | 0 (0%) | 1 (1%) | 0 (0%) | |
| IIIA1 | 1 (0.5%) | 1 (1%) | 0 (0%) | 0 (0%) | |
| IIIA2 | 4 (2%) | 4 (4%) | 0 (0%) | 0 (0%) | |
| IIIB | 6 (3%) | 3 (3%) | 3 (4%) | 0 (0%) | |
| IIIC | 28 (13%) | 13 (12%) | 10 (13%) | 5 (15%) | |
| IV | 10 (5%) | 4 (4%) | 6 (8%) | 0 (0%) | |
|
| |||||
| Upper GI Endoscopy** | |||||
| Yes | 37 (26%) | 22 (20%) | 15 (44%) | 0.007 | |
| Lower GI Endoscopy** | |||||
| Yes | 41 (28%) | 27 (24%) | 14 (41%) | 0.08 | |
| Both Upper and Lower GI Endoscopy** | |||||
| Yes | 48 (33%) | 30 (27%) | 18 (53%) | 0.007 | |
|
| |||||
| CA125 >35 U/mL (41 missing)** | |||||
| Yes | 51 (49%) | 40 (49%) | 11 (48%) | 1 | |
|
| |||||
| Tumor Size, cm (17 missing)** | |||||
| Median | 15 | 14.5 | 15 | 0.271 | |
| Range | 4.5–36 | 4.5–30 | 7–36 | ||
|
| |||||
| Capsule Rupture (12 missing) | |||||
| Yes | 71 (34%) | 47 (43%) | 19 (28%) | 5 (15%) | 0.004 |
|
| |||||
| Cytology | |||||
| Yes | 206 (93%) | 105 (95%) | 69 (90%) | 32 (94%) | 0.431 |
| Positive Cytology | |||||
| Yes | 34 (17%) | 15 (14%) | 11 (16%) | 8 (25%) | 0.361 |
|
| |||||
| Laterality** (4 missing) | |||||
| Unilateral | 134 (95%) | 102 (95%) | 32 (94%) | ||
| Bilateral | 7 (5%) | 5 (5%) | 2 (6%) | ||
|
| |||||
| Hysterectomy (2 missing) | |||||
| Yes | 164 (75%) | 70 (63%) | 68 (91%) | 26 (76%) | <0.001 |
|
| |||||
| Salpingo-oophorectomy (8 missing) | |||||
| Unilateral | 41 (19%) | 32 (29%) | 1 (1%) | 8 (24%) | <0.001 |
| Bilateral | 173 (81%) | 79 (71%) | 68 (99%) | 26 (76%) | |
|
| |||||
| Appendectomy (12 missing) | |||||
| Yes | 168 (80%) | 82 (77%) | 57 (83%) | 29 (85%) | 0.506 |
|
| |||||
| Omentectomy (5 missing) | |||||
| Yes | 196 (90%) | 100 (90%) | 63 (87.5%) | 33 (97%) | 0.296 |
|
| |||||
| Pelvic Lymphadenectomy (3 missing) | |||||
| Yes | 92 (42%) | 37 (33%) | 26 (35%) | 29 (85%) | <0.001 |
| Median | 14 | 13 | 20 | 15 | <0.001 |
| Range | 1–34 | 3–27 | 1–33 | 1–34 | |
| Number of Positive Pelvic Lymph Nodes | |||||
| 0 | 87 (95%) | 33 (89%) | 25 (96%) | 29 (100%) | – |
| 1 | 4 (4%) | 3 (8%) | 1 (4%) | 0 (0%) | |
| 2 | 1 (1%) | 1 (3%) | 0 (0%) | 0 (0%) | |
|
| |||||
| Para-aortic Lymphadenectomy (3 missing) | |||||
| Yes | 83 (38%) | 42 (38%) | 14 (19%) | 27 (79%) | <0.001 |
| Median | 11 | 16.5 | 6 | 7 | <0.001 |
| Range | 1–46 | 2–46 | 1–23 | 1–42 | |
| Number of Positive Para-aortic Lymph Nodes | |||||
| 0 | 77 (93%) | 37 (88%) | 14 (100%) | 26 (96%) | − |
| 1 | 3 (4%) | 2 (5%) | 0 (0%) | 1 (4%) | |
| 2 | 1 (1%) | 1 (2%) | 0 (0%) | 0 (0%) | |
| 5 | 2 (2%) | 2 (5%) | 0 (0%) | 0 (0%) | |
|
| |||||
| Lymphadenectomy Performed (3 missing) | |||||
| Total cohort | |||||
| Yes | 99 (45%) | 44 (40%) | 26 (35%) | 29 (85%) | |
| Stage I | |||||
| Yes | 76 (47%) | 30 (35%) | 22 (42%) | 24 (92%) | |
| Stage II – IV | |||||
| Yes | 23 (42%) | 14 (54%) | 4 (19%) | 5 (63%) | |
| Chemotherapy** | |||||
| Yes | 68 (47%) | 54 (49%) | 14 (41%) | 0.556 | |
| Number of Cycles** | |||||
| Median | 6 | 6 | 6 | 0.292 | |
| Range | 1–12 | 1–12 | 2–12 | ||
| Chemotherapy Regimen Type** | |||||
| Gynecologic | 55 (81%) | 44 (81%) | 11 (79%) | 1 | |
| Gastrointestinal | 13 (19%) | 10 (19%) | 3 (21%) | ||
GRCC, Gustave Roussy Cancer Campus; DEN, Rigshospitalet in Denmark; MSK = Memorial Sloan Kettering Cancer Center; GI = gastrointestinal
*
p values were obtained using the Kruskal-Wallis test (three centers)/Wilcoxon rank sum test (two centers) for continuous variables and the Fisher exact test for categorical variables
**
MSK and GRCC data available (N=145)